Related Experiment Video
Updated: Jul 29, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
POLE exonuclease domain mutations in endometrial carcinoma: a case report
Maria Paola Pasciuto1,2, Lara Felicioni2, Claudia Zampacorta1,2
1Center for Advanced Studies and Technology (CAST), University Chieti-Pescara, Italy.
Abstract:
Endometrial carcinoma (EC) harboring POLE exonuclease domain mutations occurs in 5-15% of ECs and frequently affects young women with low body mass index (BMI). It presents at early stage as high grade endometrioid histotype with intense tumor infiltrating lymphocytes and has good clinical outcomes and favorable prognosis. In this article we report the case of a 32-year-old woman with endometriod EC (EEC) exhibiting a "ultramutated" molecular profile and an excellent prognosis despite tumor size and grading. Herein, to highlight the importance of defining POLE status in ECs for both clinical and therapeutic implications for patients.

